Home Newsfeeds JP Morgan Downgrades Lennar to Neutral, Lowers Price Target to $80

JP Morgan Downgrades Lennar to Neutral, Lowers Price Target to $80

JP Morgan analyst Michael Rehaut downgrades Lennar (NYSE:LEN) from Overweight to Neutral and lowers the price target from $83 to $80.

byBenzinga Newsdesk

July 12, 2022

1 minute read

JP Morgan analyst Michael Rehaut downgrades Lennar (NYSE:LEN) from Overweight to Neutral and lowers the price target from $83 to $80.

Legal
News

Lithium Americas Reports Two Contractor Fatalities At Caucharí-Olaroz Lithium Project In Jujuy, Argentina On October 23

By Benzinga Newsdesk

October 24, 1:45 PM

Lithium Americas Corp. (TSX:LAC) (NYSE:LAC) ("Lithium Americas" or the "Company") is deeply saddened to report two fatalities at its Caucharí-Olaroz lithium project

LAC

Retail Earnings Paint Complex US Consumer Picture: Kohl’s Shines, Dick’s Struggles

By AJ Fabino

August 23, 12:16 PM

Recently issued earnings reports from prominent retailers paint a nuanced picture of the U.S. consumer landscape. While Kohl’s…

DKS

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today

By Benzinga Insights

August 3, 3:56 PM

Prologis (NYSE:PLD) has outperformed the market over the past 5 years by 6.0% on an annualized basis producing an average annual return of 16.88%. Currently, Prologis has a market capitalization of $95.78 billion.

PLD

FDA
News

Zhongchao Establishes Chongqing Xinjiang Pharmaceutical To Improve Patient Access To Medications

By Benzinga Newsdesk

September 28, 9:25 AM

Zhongchao Inc. (NASDAQ:ZCMD) ("Zhongchao" or the "Company"), a platform-based internet technology company offering services to patients with oncology and other major diseases, today announced

ZCMD

JP Morgan Downgrades Lennar to Neutral, Lowers Price Target to $80

Related Posts

Lithium Americas Reports Two Contractor Fatalities At Caucharí-Olaroz Lithium Project In Jujuy, Argentina On October 23

Retail Earnings Paint Complex US Consumer Picture: Kohl’s Shines, Dick’s Struggles

$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,200 Today

Zhongchao Establishes Chongqing Xinjiang Pharmaceutical To Improve Patient Access To Medications